Intermountain Homecare Hospice - Cassia 2303 Park Ave, Burley, ID, 83318 | |
(208) 678-8844 |
News Archive
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully implantable within the chest experienced no malfunctions requiring replacement or removal of the device for blood clotting.
Monarch Labs and the BioTherapeutics, Education & Research Foundation announced today their collaboration to develop two fecal microbiota transplantation products.
Amylin Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2010. The Company reported total revenue of $174.1 million for the quarter ended March 31, 2010, which includes net product sales of $172.3 million. Non-GAAP operating loss was $3.8 million for the quarter ended March 31, 2010, compared to $19.9 million for the same period in 2009.
A unique Beta 1,3-1,6 Glucan based Japanese health supplement, produced by black yeast, Aureobasidium Pullulans, could strategically help tackle Covid-19 in people with comorbid conditions like diabetes, kidney and heart diseases, as published in Frontiers in Immunology Journal recommending clinical studies, for validation.
› Verified 8 days ago
Name | Intermountain Homecare Hospice - Cassia |
---|---|
Location | 2303 Park Ave, Burley, Idaho |
Hospice ID | 131542 |
Category | Freestanding Hospice |
Ownership Type | Other |
Profit Type | OTHER |
SSA county code | 150 |
News Archive
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully implantable within the chest experienced no malfunctions requiring replacement or removal of the device for blood clotting.
Monarch Labs and the BioTherapeutics, Education & Research Foundation announced today their collaboration to develop two fecal microbiota transplantation products.
Amylin Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2010. The Company reported total revenue of $174.1 million for the quarter ended March 31, 2010, which includes net product sales of $172.3 million. Non-GAAP operating loss was $3.8 million for the quarter ended March 31, 2010, compared to $19.9 million for the same period in 2009.
A unique Beta 1,3-1,6 Glucan based Japanese health supplement, produced by black yeast, Aureobasidium Pullulans, could strategically help tackle Covid-19 in people with comorbid conditions like diabetes, kidney and heart diseases, as published in Frontiers in Immunology Journal recommending clinical studies, for validation.
› Verified 8 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 98.4 | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 93.7 | 93.6 |
Patients who were checked for pain at the beginning of hospice care | 87.3 | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | 92.5 | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | 96.8 | 97.3 |
Patients who got timely treatment for shortness of breath | 93.0 | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | 95.7 | 93.3 |
News Archive
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully implantable within the chest experienced no malfunctions requiring replacement or removal of the device for blood clotting.
Monarch Labs and the BioTherapeutics, Education & Research Foundation announced today their collaboration to develop two fecal microbiota transplantation products.
Amylin Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2010. The Company reported total revenue of $174.1 million for the quarter ended March 31, 2010, which includes net product sales of $172.3 million. Non-GAAP operating loss was $3.8 million for the quarter ended March 31, 2010, compared to $19.9 million for the same period in 2009.
A unique Beta 1,3-1,6 Glucan based Japanese health supplement, produced by black yeast, Aureobasidium Pullulans, could strategically help tackle Covid-19 in people with comorbid conditions like diabetes, kidney and heart diseases, as published in Frontiers in Immunology Journal recommending clinical studies, for validation.
› Verified 8 days ago
Home Health Aides | 2 |
Counselors | 0.25 |
Medical Social Workers | 1 |
Physicians | 1 |
Registered Nurses | 6 |
Other Personnel | 0.1 |
Total Employees | 10.35 |
---|
News Archive
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully implantable within the chest experienced no malfunctions requiring replacement or removal of the device for blood clotting.
Monarch Labs and the BioTherapeutics, Education & Research Foundation announced today their collaboration to develop two fecal microbiota transplantation products.
Amylin Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2010. The Company reported total revenue of $174.1 million for the quarter ended March 31, 2010, which includes net product sales of $172.3 million. Non-GAAP operating loss was $3.8 million for the quarter ended March 31, 2010, compared to $19.9 million for the same period in 2009.
A unique Beta 1,3-1,6 Glucan based Japanese health supplement, produced by black yeast, Aureobasidium Pullulans, could strategically help tackle Covid-19 in people with comorbid conditions like diabetes, kidney and heart diseases, as published in Frontiers in Immunology Journal recommending clinical studies, for validation.
› Verified 8 days ago
Intermountain Homecare Hospice - Cassia Location: 2303 Park Ave, Burley, Idaho, 83318 Phone: (208) 678-8844 |